Where Will AbbVie Be in 5 Years?
In some ways, (NYSE: ABBV) isn't the same company it was five years ago. Sure, it's still in the biopharmaceuticals business. However, AbbVie has a new CEO. More importantly, it no longer depends on Humira for roughly 37% of total revenue.
Today, AbbVie can see its Humira patent cliff in the rearview mirror. But what does the view look like through the front windshield? Where will AbbVie be in five years?
Image source: Getty Images.
Source Fool.com
AbbVie Inc. Stock
€194.80
1.470%
The stock is an absolute favorite of our community with 31 Buy predictions and no Sell predictions.
As a result the target price of 210 € shows a slightly positive potential of 7.8% compared to the current price of 194.8 € for AbbVie Inc..
